One hundred and eighty three hypertensive pregnant women were randomly assigned to antihypertensive treatment with oxprenolol (96 women) or methyldopa (87 women). Control of hypertension was equivalent in both treatment groups, and in 64 (35%) cases hydralazine had to be added to the treatment to achieve the therapeutic goal (diastolic blood pressure below 85 mm Hg). Five perinatal deaths occurred, one in the oxprenolol group and four in the methyldopa group. Detailed analysis confirmed a previous report of greater fetal growth in the group treated with oxprenolol; this trend was present regardless of severity of hypertension and parity. With
Introduction
Hypertension in pregnancy, whatever its aetiology, remains the most common medical cause of both maternal and perinatal morbidity and mortality. ' Gallery. trol of hypertension reduces these complications,2-4 although the choice of antihypertensive agent is controversial. 5 We previously reported preliminary results of the first randomised comparison of a 3 adrenoceptor blocking agent and the centrally acting agent methyldopa for the treatment of hypertension in pregnancy.8 This report deals with the completed study, in which 183 pregnant women participated.
Patients and methods
All patients included in the study were attending this hospital for antenatal care. One hundred and eighty three women with singleton pregnancies complicated by hypertension were allocated by a series of random numbers to treatment with either oxprenolol or methyldopa. Neither the patient nor the doctor was blinded regarding treatment. The criterion for entry into the study was a sitting diastolic blood pressure (phase IV, Korotkoff sounds) of 90 mm Hg or above on two occasions at least 24 hours apart, 95 mm Hg or above on two occasions 12 hours apart, or 100 mm Hg or above on two occasions eight hours apart. On each occasion the mean of two readings taken one minute apart after the patient had been sitting quietly for 10 minutes was recorded. All patients were inpatients at the time of starting treatment and remained so until adequate control of blood pressure was achieved. After this patients were treated as outpatients unless there was a specific indication to remain in hospital. Outpatients were seen fortnightly until 28 weeks of amenorrhoea and weekly thereafter, alternately by their own obstetricians and at a special medical obstetrical clinic. Inpatients were seen and assessed daily.
Oxprenolol where SS=sums of squares for the group treated with oxprenolol (0), N1 = total number of patients in the group treated with oxprenolol, SS2 =sums of square for the group treated with methyldopa (M), and N2 =total number of patients in the group treated with methyldopa. Significance was then tested for mean weights of treatment groups at different durations of treatment (with diastolic blood pressure before treatment fixed at intervals from 85 to 100 mm Hg) by the formula: mean 0-mean M SE of difference (as calculated above)
Results
The two groups were comparable in age, height, weight, parity, severity of hypertension, and stage of pregnancy at which treatment Weeks' gestation at start of treatment* 29 ( 1 2) 30 (1 7) 30 (1 1) 31 ( *Calculations exclude nine women given oxprenolol and eight given methyldopa transferred from other treatments, all before 20 weeks' amenorrhoea. To achieve this hydralazine had to be added to the therapeutic regimen in 64 (35%) patients and the third agent had to be added (that is, methyldopa to the combination of oxprenolol and hydralazine, or oxprenolol to the combination of methyldopa and hydralazine) in 12 (7%) patients, with minor differences between the groups not achieving significance (table II) .
There was no significant difference between the groups in the duration of pregnancy at the time of delivery, and no patient in either group went into spontaneous labour before the 28th week of gestation. Table   III shows the indications for delivery: acceleration of maternal disease was the indication in 10 (11%) of the patients treated with oxprenolol and 10 (12%) of those treated with methyldopa.
Tables IV and V summarise the perinatal outcome. Mean birth weights in both treatment groups were within the normal range for the total population at this hospital, though they were somewhat higher in the women treated with oxprenolol than in those treated with methyldopa (p < 005).
Overall, babies born to primigravidas were smaller than those born to multiparous women, and boys were slightly heavier than girls. Babies of women who required only one antihypertensive agent for control of blood pressure were bigger than those of women with more severe hypertension, and there was no significant difference in birth weights between the oxprenolol and methyldopa groups in these mildly hypertensive women. Apgar scores at birth and at five minutes were satisfactory in most babies in both groups, and hypoglycaernia was not a major concern.
Overall, 34 (190/) babies required admission to the intensive care
In this study we analysed, in some detail, the effects of treatment on both mothers and babies. Primigravidas were analysed both as part of the whole groups and separately, as this subdivision is most likely to include a high proportion of women with hypertension associated with pregnancy (pre-eclampsia). Such patients might be expected to have a more complicated course and less satisfactory fetal outcome, although the clinical course of chronic hypertension of the severity described in this study is poor, with perinatal mortality as high as 30% in earlier reports'6 and of 8-9% in recent large multicentre studies.'7
The outcome of treatment and of pregnancy was the same in primigravidas as in the groups overall. The severity and degree of control of hypertension were the same, and, apart from a trend towards higher rates of caesarean section (which were high overall, reflecting the high risk nature of this group of pregnant women), there were no significant differences from the total group in either maternal or fetal outcome of pregnancy. One area of concern is the superimposition of hypertension associated with pregnancy in chronically hypertensive women and its progression despite control of blood pressure. The diagnosis of this condition can be extremely difficult, as described in Pollak and Nettle's classic review of renal biopsy material. '8 Primigravidas are particularly susceptible to hypertension associated with pregnancy, but they may also have chronic hypertension, even without a relevant personal or family history. Ten women in each group in our study required urgent delivery because of the severity of their disease. All of these women had heavy and increasing proteinuria, which developed after the start of treatment in four patients given oxprenolol and five given methyldopa. This may seem a high incidence of complications but is again considerably better than the reported incidence of the development of proteinuria in untreated patients with this severity of hypertension." This finding supports others reported recently after use of another f adrenoceptor blocking agent, atenolol,'2 suggesting that control of hypertension does have a preventive effect on superimposed pre-eclampsia.
In our original report, which dealt with 53 women with diastolic blood pressures of over 100 mm Hg before treatment, we found a highly significant difference between mean birth weights of babies born to women treated with oxprenolol and 31 AUGUST 1985 those born to women treated with met'iyldopa (97% v 86% of normal for gestational age, p <0-001). Although the same trend was apparent in these results, the difference between the groups was less (97% v 92% of normal), in part because the hypertension before treatment was less severe in both groups of women. Tables III-V show more detailed analyses of these results and cover other factors known to affect potential fetal growth. In both groups male infants were heavier at birth than female infants, and multiparous women had heavier babies than primigravidas. Although there was an overall trend in those treated with oxprenolol towards heavier babies, and thus fewer neonatal problems requiring observation in the neonatal intensive care unit, differences failed to achieve significance in some subgroups, probably because of the small numbers studied.
A study in Britain in 1983 comparing oxprenolol and methyldopa for the treatment of hypertension in pregnancy failed to confirm our earlier findings regarding birth weight," although they were supported by a study in New Zealand." One of the major difficulties in comparing studies of this type is nonuniformity of selection of patients and of criteria for subsequent control of hypertension. The major difference between the British study and our previous report was the therapeutic goal during the periods of treatment (diastolic blood pressure <95 mm Hg as against <85 mm Hg, respectively). It is unclear from the results presented by Fidler et al how well the therapeutic aim was achieved." These clinical therapeutic factors may not at first appear important, but it may well be that patients reported on in that study had considerably raised blood pressures for considerable periods, even while taking antihypertensives. The administration of a therapeutic agent is not a sufficient condition for assuming therapeutic efficacy, and the degree of control of hypertension may have been a critical factor in the results that we reported earlier. The smaller differences that we report here may well represent inclusion of patients with less severe hypertension and therefore less expected retardation of intrauterine growth.
To investigate this possibility more closely the outcome variable of birth weight was analysed by multiple regression and results compared for the two treatment groups according to severity of hypertension before treatment and duration of treatment. The figure shows the results of this regression analysis, with birth weight corrected for gestational age, for the treatment groups overall and for primigravidas separately (diastolic blood pressure before treatment fixed at 90 or 100 mm Hg). These results confirm the difference between the two drugs in the effect on fetal growth that we found earlier, with significantly heavier babies in the group treated with oxprenolol. As *p<005, **p<001, ***p<O0001.
sion and was present equally in the primigravidas and in the total group. From this analysis came another interesting and potentially valuable finding, which may explain some of the differences found in several other therapeutic studies. With increasing duration of treatment the differences between the two treatment groups became less, and after eight weeks of treatment in those with less severe hypertension (12 weeks in those with diastolic blood pressure before treatment > 100 mm Hg) the differences between the two groups were no longer significant. In our preliminary report we postulated, from studies of plasma volume and haemodynamics, that the potential benefit to fetal growth from treatment with oxprenolol might be due to peripheral vasodilatation, perhaps secondary to the intrinsic sympathomimetic activity of that agent, rather than simply to control of hypertension, as this variable was controlled equally well in both patient groups. The results presented here are in keeping with that hypothesis, and we would suggest that over time a similar effect can be obtained by adequate control of hypertension, as shown by the reduction of the difference between the two groups with increasing duration of treatment. This is probably a response to adequate long term control of hypertension per se and therefore separate from the specific early vasodilatation resulting from treatment with oxprenolol.
It appears, therefore, that control of hypertension can be associated with good fetal growth if that control is adequate and can be continued for a sufficient period. The long term effects of treatment are probably similar to those in non-pregnant women, with some relief of vasoconstriction, some retention of salt and water, and expansion of plasma volume, although confirmation of this will require measurement of the appropriate variables.
Clearly, for short term treatment there is potential fetal benefit from treatment with oxprenolol. Twenty nine (16%) patients could have treatment for only two weeks or less, and it was during this time that the most pronounced difference was seen between the two treatment groups. As hypertension in pregnancy (whatever its underlying cause) may pursue an accelerated course, and it is uncertain in advance in which patients this is likely to occur, initial treatment with oxprenolol seems most reasonable. This would be our recommendation, provided that there is no maternal contraindication to the administration of 3 blocking agents.
